Science Translational Medicine

metrics 2024

Translating Science into Solutions.

Introduction

Science Translational Medicine is a premier journal published by the American Association for the Advancement of Science, dedicated to bridging the gap between laboratory discovery and clinical application. With an impressive impact factor and a Q1 categorization in the field of Medicine, it is recognized as one of the leading journals, ranking 11 out of 636 in general medicine according to Scopus, placing it in the top 2% of its category. Since its inception in 2009, the journal has been at the forefront of innovative research, presenting high-quality studies that translate scientific advancements into tangible medical solutions. Researchers, professionals, and students alike will find its rich content invaluable for staying informed on cutting-edge developments in the field. The journal's commitment to accessibility ensures that the latest findings and insights are available to a global audience, fostering collaboration and scientific progress.

Metrics 2024

SCIMAGO Journal Rank6.51
Journal Impact Factor15.80
Journal Impact Factor (5 years)16.90
H-Index284
Journal IF Without Self15.80
Eigen Factor0.08
Normal Eigen Factor18.12
Influence6.96
Immediacy Index3.30
Cited Half Life6.10
Citing Half Life7.10
JCI3.51
Total Documents6136
WOS Total Citations50866
SCIMAGO Total Citations154248
SCIMAGO SELF Citations1365
Scopus Journal Rank6.51
Cites / Document (2 Years)14.71
Cites / Document (3 Years)13.43
Cites / Document (4 Years)13.04

Metrics History

Rank 2024

Scopus

General Medicine in Medicine
Rank #11/636
Percentile 98.27
Quartile Q1

IF (Web Of Science)

CELL BIOLOGY
Rank 11/205
Percentile 94.90
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 2/189
Percentile 99.20
Quartile Q1

JCI (Web Of Science)

CELL BIOLOGY
Rank 9/205
Percentile 95.61
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 3/189
Percentile 98.41
Quartile Q1

Quartile History

Similar Journals

Translational Medicine at UniSa

Catalyzing Innovations for Improved Patient Lives
Publisher: UNIV STUDI SALERNOISSN: 2239-9747Frequency: 3 issues/year

Translational Medicine at UniSa, published by the esteemed UNIV STUDI SALERNO, serves as a pivotal platform for disseminating innovative research in the field of translational medicine. With its ISSN 2239-9747, this journal aims to bridge the gap between laboratory research and clinical application, facilitating the transformation of scientific findings into practical healthcare solutions. Committed to fostering collaboration among researchers, clinicians, and educators, Translational Medicine at UniSa aspires to enhance evidence-based medicine practices and improve patient outcomes. Although the journal is not currently open access, its rigorous peer-review process ensures that only high-quality research reaches its audience. As an influential publication in the realm of medical research, it is essential for professionals, researchers, and students seeking to stay at the forefront of advancements in translational medicine.

IN VIVO

Advancing cancer research through innovative insights.
Publisher: INT INST ANTICANCER RESEARCHISSN: 0258-851XFrequency: 6 issues/year

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Advances in Laboratory Medicine-Avances en Medicina de Laboratorio

Elevating Standards in Laboratory Medicine.
Publisher: WALTER DE GRUYTER GMBHISSN: Frequency: 4 issues/year

Advances in Laboratory Medicine - Avances en Medicina de Laboratorio is a distinguished open-access journal published by Walter de Gruyter GmbH, dedicated to the field of medical laboratory technology and the broader aspects of laboratory medicine. Launched in 2020, this journal aims to disseminate high-quality research, innovative methodologies, and critical reviews that foster advancements in laboratory practices. With significant rankings, including Q3 in Medical Laboratory Technology and Q4 in Education and Medicine (miscellaneous) as of 2023, it serves as a vital resource for researchers, professionals, and students interested in enhancing their understanding and implementation of laboratory protocols. Based in Germany, the journal not only emphasizes accessibility through its open-access model but also contributes significantly to the evolving landscape of medical laboratory science. Join a community of scholars striving to improve patient outcomes and elevate standards within the laboratory domain.

Revista Romana de Medicina de Laborator

Pioneering Research for a Healthier Tomorrow
Publisher: SCIENDOISSN: 1841-6624Frequency: 4 issues/year

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.

Cell Reports Medicine

Bridging molecular discoveries and clinical innovations.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Cancer Discovery

Pioneering Insights in Cancer Prevention and Treatment
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

Translational Research

Fostering Collaboration for a Healthier Future
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

EXPERT OPINION ON THERAPEUTIC TARGETS

Empowering researchers with cutting-edge perspectives on treatment targets.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

JOURNAL OF MOLECULAR MEDICINE-JMM

Pioneering Insights in Drug Discovery and Genetics.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

ACS Pharmacology & Translational Science

Connecting research and practice in pharmacology.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.